Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principle
Judit Sánchez Gil, Maxime Dubois, Virginie Neirinckx, Arnaud Lombard, Natacha Coppieters, Paolo D’Arrigo, Damla Isci, Therese Aldenhoff, Benoît Brouwers, Cédric Lassence, Bernard Rogister, Marielle Lebrun, Catherine Sadzot‐Delvaux
Abstract
orthotopic xenograft mouse model, this oHSV slows down tumor growth and significantly improves mice survival. Customizing oHSVs with diverse nanobodies for targeting multiple proteins appears as an interesting approach for tackling the heterogeneity of GBM, especially GSCs. Altogether, our study must be considered as a proof of principle and a first step toward personalized GBM virotherapies to complement current treatments.
Topics & Concepts
Oncolytic virusCXCR4Cancer researchCancer cellCancerVirotherapyApoptosisBiologyChemokineImmunologyTumor cellsGeneticsImmune systemVirus-based gene therapy researchImmunotherapy and Immune ResponsesCytomegalovirus and herpesvirus research